The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 42 | — | 20.1x | Near average | |
Growth | 22 | — | 5.6% | Below average | |
Quality | 49 | 556.6% | 7.6% | Near average | |
Safety | 31 | 0.1x | 0.4x | Below average | |
Capital Return | 20 | 0.00% | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Immunic, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Immunic, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The analyst outlook for Immunic has recently experienced sharp divergence and uncertainty; while the average price target stabilized at 14.5 dollars, the number of analysts covering the stock decreased from 7 to 4, indicating a decline in institutional consensus. There is significant dispersion in forecasts between a low of 2.5 dollars and a high of 22 dollars, reflecting ambiguity regarding future clinical or financial results, especially with expectations of continued losses in earnings per share (EPS) for 2024.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.